Literature DB >> 11401410

Gastric motor effects of triptans: open questions and future perspectives.

G Cipolla1, S Sacco, F Crema, E Moro, F De Ponti, G Frigo.   

Abstract

Sumatriptan is a 5-HT1B/D receptor agonist of documented efficacy in relieving migraine and associated symptoms such as nausea and vomiting. In the past decade, several studies reported an important delay of gastric emptying induced by sumatriptan in healthy humans. The impact of this gastric motor effect of sumatriptan in migraineurs is difficult to predict: a further delay in gastric emptying could be detrimental (i.e. increased nausea and epigastric symptoms) in patients already having delayed gastric emptying. However, in patients with functional dyspepsia, sumatriptan is also reported to improve gastric accommodation to a meal and reduce perception of gastric distention, hence relieving epigastric symptoms. Thus, reduced visceral perception could be a mechanism involved in reducing nausea during a migraine attack. Paradoxically, sumatriptan is reported both to relieve the nausea of a migraine attack and to have nausea as a side effect. Although careful analysis of the time of onset of nausea may offer a clue as to the origin of this symptom, available data do not support definite conclusions, all the more so because the gastric motor effect of second-generation triptans are still unexplored. Taken together, the available evidence warrants further studies to clarify the following issues: first, the mechanism responsible for the gastric motor effect of sumatriptan [receptor subtype(s) involved; central vs peripheral mechanism]; secondly, the effects on gastric motility/visceral sensitivity of second-generation triptans (which are 5-HT1B/D receptor agonists) and more recent selective 5-HT1D receptor agonists (proposed as investigational antimigraine agents with less potential to induce coronary vasoconstriction through 5-HT1B receptors); finally, the possible use of drugs improving gastric accommodation to a meal in the management of those dyspeptic patients with impaired fundic relaxation/altered visceral sensitivity. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401410     DOI: 10.1006/phrs.2000.0766

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  Effect of sumatriptan on gastric emptying: a crossover study using the BreathID system.

Authors:  Yasunari Sakamoto; Yusuke Sekino; Eiji Yamada; Takuma Higurashi; Hidenori Ohkubo; Eiji Sakai; Hiroki Endo; Hiroshi Iida; Takashi Nonaka; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Ayumu Goto; Yasunobu Abe; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

Review 2.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Non-oral formulations of triptans and their use in acute migraine.

Authors:  Carl G H Dahlöf
Journal:  Curr Pain Headache Rep       Date:  2005-06

Review 4.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Cutaneous allodynia and migraine: another view.

Authors:  Carl Dahlöf
Journal:  Curr Pain Headache Rep       Date:  2006-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.